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Introduction
Malignant glioma tumors are the most common primary central nervous system (CNS) tumors and account for 78% of overall CNS tumors in adults. 1 The current standard of care for the treatment of malignant glioma are surgery, radiotherapy and chemotherapy. 2 Despite the multidisciplinary approach to treatment, prognosis remains poor and progression of disease is relatively common. [3] [4] [5] [6] There have been reports since the early 19 th century that cancer patients who have been infected with bacteria have shown regression of their tumors. 7 At the end of the 19 th century, Coley treated cancer patients with bacteria and later used extracts of the bacteria, called Coley's toxins, as a therapeutic. Coley's toxins showed significant efficacy in a large group of cancer patients. 8 Coley's toxins went out of favor after his death in the 1930s. Starting in the mid -20 th century, there were preclinical studies on bacterial therapy of cancer and recently studies have been performed with obligate anaerobes such as Bifidobacterium and Clostridium in mouse models of cancer. [9] [10] [11] [12] [13] [14] However, obligate anaerobes can only grow in the necrotic areas of tumors, which limits their efficacy. The facultative anaerobe Salmonella typhimurium (S. typhimurium) has also been attenuated for use as an anticancer agent and tested in a clinical trial. 15 Although the Phase I clinical trial showed safety of this approach, tumor colonization by the bacteria was limited, perhaps due to over-attenuation.
We have previously developed S. typhimurium A1, which is auxotrophic (leu/arg-dependent) but receives sufficient nutritional support from tumor tissue. However, S. typhimurium A1-R does not continuously infect normal tissues.
To increase the tumor-targeting capability of S. typhimurium A1, the strain was re-isolated after infection into a human colon tumor growing in nude mice. The tumor-isolated strain, termed A1-R, demonstrated efficacy in treatment of mouse models of human breast cancer, 16 human prostate cancer, 17 fibrosarcoma,
The bacteria therapy was evaluated by tumor volume, which was measured using fluorescence imaging. Efficacy of the bacteria treatment is shown in Figure 3B . Average tumor size on day 14 (the day S. typhimurium A1-R was administered) was 1. Survival efficacy of S. typhimurium A1-R therapy on U87-RFP glioma. Survival efficacy of S. typhimurium A1-R therapy in the orthotopic model is shown in Figure 4 . Death from disease was rapid in the control group and intravenous group. Their median survival times were 37 and 43 d, respectively. Treatment with intracranial injection significantly prolonged median survival to 64 d (p = 0.001). Two out of seven mice treated by intracranial injection survived at day 80.
Intracranial injection of S. typhimurium was significantly more effective and resulted in prolonged survival in mice compared with intravenous injection (Figs. 3 and 4 ). It appears that S. typhimurium poorly penetrates the blood-brain barrier. Unlike systemic therapy, intracranial injection of S. typhimurium A1-R can bypass the blood-brain barrier, which is the major obstacle in treatment of brain cancer. Intracranial administration delivers S. typhimurium A1-R directly to the brain tumor.
U87 glioma tumors in the brain were observed through the craniotomy open window (Fig. 1A) . The craniotomy open window enables imaging tumor growth in the brain over time while keeping animals alive and without further invasive procedures. Colonies of GFP-labeled S. typhimurium A1-R were observed in the U87-RFP brain tumor after cranial injection, but no bacterial colonies were found in the tumor treated with intravenous injection of S. typhimurium A1-R (Fig. 1B) .
Dose-limiting toxicity of S. typhimurium A1-R administered by intracranial injection. Mice without tumors were tested for determination of S. typhimurium A1-R dose-limiting toxicity after intracranial administration of the bacteria. The mice were injected intracranially weekly with different doses of the bacteria (5 x 10 5 CFU/μl, 1 x 10 6 CFU/μl and 2 x 10 6 CFU/μl). The body weight ratio (body weight at each day/body weight at day 0) was compared in the three groups to determine toxicity (Fig. 2) . In the 5 x 10 5 CFU/μl and 1 x 10 6 CFU/ μl groups, the maximum weight loss was 13.7% and 11.2%, respectively, and weight recovered by day 14 in both groups. In the 2 x 10 6 CFU/μl group, however, the maximum weight loss was 35.9% on day 5, exceeding 20% weight loss, and by day 14, body weight did not recover. The treatment dose of S. typhimurium A1-R for brain cancer was therefore chosen as 1 x 10 6 CFU/μl. Evaluation of S. typhimurium A1-R therapeutic brain cancer efficacy over time. Mice in the treatment group were given S. typhimurium A1-R weekly by intravenous injection (i.v.) or intracranial injection (i.c.) for 3 weeks, beginning 14 d after tumor transplantation. Mice were administered the same volume of PBS as the untreated group (control). Tumor size was measured using RFP imaging at days 14, 21, 28 and 35 (Fig. 3A) . (5 x 10 5 CFU/μl, 1 x 10 6 CFU/μl and 2 x 10 6 CFU/μl). the body weight ratio was compared within three groups to decide the optional dosage of the bacteria. In the 5 x 10 5 CFU/μl and 1 x 10 6 CFU/μl groups, the maximum weight loss was 13.7% and 11.2%, respectively, and weight recovered by day 14 in both groups. In the 2 x 10 6 CFU/μl group, however, the maximum weight loss was 35.9% on day 5, and on day 14, the weight loss was still 12.9%. the optimal dose of S. typhimurium A1-R in the brain was therefore determined to be 1 x 10 6 CFU/μl.
S. typhimurium A1-R is auxotrophic for both leucine and arginine, which appears to preclude these bacteria from mounting a sustained infection in normal tissue. Tumors, however, appear to be able to supply these amino acids sufficiently and enable S. typhimurium A1-R to grow in and kill tumors. 25 S. typhimurium A1-R was selected for increased virulence by passage through a growing tumor in a mouse. 16 Weekly administration of bacteria at the appropriate dose by intracranial delivery had no apparent adverse effects (such as meningitis, encephalitis). The mice tolerated the treatment well and appeared healthy during the experiment. These safety results suggest that direct cranial injection of bacteria in patients with brain cancer could be a clinically effective method for treatment of this highly drug-resistance disease.
In conclusion, we have demonstrated that S. typhimurium A1-R monotherapy rapidly inhibits human U87 glioma in the (B) tumor volumes in each group were compared. tumor volume in the intracranial-injection group was significantly smaller than in the other two groups (at day 35, vs. control: p = 0.009; vs. intravenous: p = 0.014). However, there was no significant difference in tumor volume between the control group and intravenous-injection group. Seven mice were used in each group. the experimental data are expressed as the mean ± SD. Statistical analysis was performed using the Student t-test. Our results also suggest potential use of S. typhimurium A1-R to target 26 glioma properties such as delivery of glioma-suppressing microRNAs; 27 targeting enzymes involved with aerobic glycolysis; 28 targeting the hypoxic glioma tumor microenvironment 29 and targeting the Tie2/TEK tyrosine kinase receptor.
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Materials and Methods
Establishment of RFP labeled cancer cell line. For RFP gene transduction of cancer cells, 70% confluent human glioma (U87) cells were used. In brief, cells were incubated with a 1:1 precipitated mixture of retroviral supernatants of PT67-RFP cells and RPMI 1640 (Irvine Scientific) containing 10% fetal bovine serum (FBS) (Hyclone Laboratories) for 72 h. Fresh medium was replenished at this time. Cells were harvested with trypsin/ EDTA 72 h post-transduction and subcultured at a ratio of 1:15 into selective medium, which contained 200 μg/ml of G418. The level of G418 was increased stepwise up to 800 μg/ ml. Cell culture. U87 cells were maintained in DMEM medium (Hyclone Laboratories) supplemented with 10% FBS. The cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. The cells were collected after trypsinization and stained with trypan blue (Sigma-Aldrich). Only viable cells were counted with a hemocytometer (Hausser Scientific).
Green fluorescent protein (GFP) gene transfection of S. typhimurium. S. typhimurium (ATCC 14028) was grown at directly down the midline of the scalp. The scalp was retracted and the skull was exposed. Using a skin biopsy punch (Acuderm Inc.), a 4 mm diameter craniotomy was made over the right parietal bone (Fig. 1A) . The bone fragment was removed carefully in order not to injure the meninges and brain tissue. The craniotomy open window was covered only by the scalp. Thus, only scalp retraction was needed in order to image tumor growth or inject S. typhimurium in the brain. The incision was then closed with 6-0 surgical suture (ETHICON, Inc.). All mice were kept in an oxygenated warmed chamber until they recovered from anesthesia.
Stereotactic injection. The mice were anesthetized with a ketamine mixture via s.c. injection. After the craniotomy open window was made, 1 μl of a suspension containing 2 x 10 5 U87-RFP cells was injected stereotactically into the mouse brain using a 10 μl Hamilton syringe. Cells were injected in the middle of the craniotomy open window to a depth of 1 mm.
Bacterial therapy in the brain tumor model. Two weeks after inoculation, mice were treated with S. typhimurium A1-R (2 x 10 7 CFU/200 μl PBS intravenous injection from the tail vein or 1 x 10 6 CFU/1 μl PBS intracranial injection through the craniotomy open window) once a week for 3 weeks. Mice were administered the same volume of PBS as the untreated control group. After administration of S. typhimurium A1-R, fluorescence imaging (please see below) was performed (Fig. 1A) and changes in the diameters of the RFP-expressing tumors were recorded each week for 3 weeks. Tumor diameters were measured each week after S. typhimurium A1-R administration. Tumor volume was calculated by the formula (width 2 x length x 0.5). Seven mice were used in each group.
Fluorescence imaging. The Olympus OV100 Small Animal Imaging System (Olympus), containing an MT-20 light source (Olympus Biosystems) and DP70 CCD camera (Olympus), was used for imaging live mice. 34 High-resolution images were captured directly on a personal computer (Fujitsu Siemens Computers). Images were analyzed with the use of Cell R software (Olympus Biosystems).
Survival analysis. The experimental data are expressed as the mean ± SD. Statistical analysis was performed using the Student t-test. Kaplan-Meier analysis with a log-rank test was used to determine survival and difference between treatment groups. A p-value less than 0.05 was used to indicate a significant difference.
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37°C to mid-logarithmic phase in liquid Luria Bertani (LB) and harvested at 4°C. Bacteria (2.0 x 10 8 ), in 40 μl 10% glycerol, were mixed with 2 μl pEGFP vector (Clontech). The preparation was placed on ice for 5 min before electroporation, using the Gene Pulser apparatus (Bio-Rad) according to the manufacturer's instructions. Electroporation was performed at 1.8 kV, with the pulse controller at 1,000 Ω parallel resistance. 31 Bacteria engineered to express light-emitting proteins have been shown to be readily visualized in tumors. 32, 33 Induction of bacterial mutations with nitrosoguanidine and selection for auxotrophs of S. typhimurium-GFP. Freshly prepared nitrosoguanidine (NTG; 1 mg/ml in sterile water) was added to the washed culture to a final concentration of 100 μg/ ml in Tris-maleic acid buffer (pH 6.0). S. typhimurium-GFP were incubated with NTG for 30 min. NTG-treated cells were grown in nutrient broth to express any mutations that had been induced. Bacterial colonies were replica-plated in supplemented minimal agar plates, containing specific amino acids in order to identify auxotrophic requirements. Auxotroph A1, which required leucine and arginine, was initially isolated.
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Selection of the high-tumor-targeting variant S. typhimurium A1-R. Selection of a high-tumor-targeting variant of S. typhimurium A1-GFP was performed as follows: A1 bacteria were injected into the tail vein of an HT-29 human colon tumorbearing nude mouse. Three days after infection, tumor tissue was removed from the infected animal. Tumor tissue was then homogenized and diluted with phosphate-buffered saline (PBS). The resulting supernatant of the tumor tissue was cultured in LB agar plates at 37°C overnight. The bacterial colony with the brightest green fluorescence was selected and cultured in 5 ml of LB medium. This strain was termed A1-R. 16 Growth of S. typhimurium A1-R for treatment. S. typhimurium A1-R were grown overnight in LB medium and then diluted 1:10 in LB medium. Bacteria were harvested at latelog phase, washed with PBS and then diluted in PBS. Bacteria were then ready for injection in mice. 16 Animals. Athymic NCR nude mice (nu/nu) at 4-6 weeks of age were used in this study. The breeding pairs were obtained from Charles River Laboratories. Mice were kept in a barrier facility under HEPA filtration. Mice were fed with autoclaved laboratory rodent diet. All animal studies were conducted in accordance with the principals and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals under PHS Assurance Number A3873-1.
Craniotomy open window. Mice were anesthetized with a ketamine mixture (10 μl ketamine HCL, 7.6 μl xylazine, 2.4 μl acepromazine maleate and 10 μl H 2 O) via s.c. injection. After fixing the mice in a prone position, a 1.5 cm incision was made
